IR Licensing and Partnerships

February 12th 2025

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

January 30th 2025

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung cancer who are PD-1 checkpoint inhibitor resistant.